Clover Health Investments Corp. Cl A (CLOV): Price and Financial Metrics

Clover Health Investments Corp. Cl A (CLOV): $2.13

-0.12 (-5.33%)

POWR Rating

Component Grades














  • Momentum is the dimension where CLOV ranks best; there it ranks ahead of 38.1% of US stocks.
  • CLOV's strongest trending metric is Value; it's been moving up over the last 179 days.
  • CLOV ranks lowest in Stability; there it ranks in the 0th percentile.

CLOV Stock Summary

  • Clover Health Investments Corp's stock had its IPO on April 22, 2020, making it an older stock than merely 5.17% of US equities in our set.
  • In terms of twelve month growth in earnings before interest and taxes, Clover Health Investments Corp is reporting a growth rate of 295.9%; that's higher than 92.79% of US stocks.
  • The volatility of Clover Health Investments Corp's share price is greater than that of 95.63% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Clover Health Investments Corp are AXU, OSH, LOTZ, CLB, and BLNK.
  • CLOV's SEC filings can be seen here. And to visit Clover Health Investments Corp's official web site, go to

CLOV Valuation Summary

  • In comparison to the median Healthcare stock, CLOV's price/earnings ratio is 119.18% lower, now standing at -7.
  • Over the past 17 months, CLOV's EV/EBIT ratio has gone down 4.6.
  • Over the past 17 months, CLOV's EV/EBIT ratio has gone down 4.6.

Below are key valuation metrics over time for CLOV.

Stock Date P/S P/B P/E EV/EBIT
CLOV 2021-08-31 2.7 11.3 -7.0 -6.6
CLOV 2021-08-30 2.7 11.2 -6.9 -6.5
CLOV 2021-08-27 2.7 11.4 -7.0 -6.6
CLOV 2021-08-26 2.7 11.2 -6.9 -6.5
CLOV 2021-08-25 2.8 11.5 -7.1 -6.7
CLOV 2021-08-24 2.8 11.8 -7.3 -6.9

CLOV's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CLOV has a Quality Grade of C, ranking ahead of 33.49% of graded US stocks.
  • CLOV's asset turnover comes in at 1.618 -- ranking 5th of 133 Insurance stocks.
  • 500 - Internal server error

The table below shows CLOV's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.618 0.009 -0.991
2021-03-31 1.251 0.098 -0.276
2020-12-31 1.398 0.148 -0.223
2020-09-30 1.222 0.222 0.038
2020-09-30 0.000 NA -0.006

CLOV Price Target

For more insight on analysts targets of CLOV, see our CLOV price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.00 Average Broker Recommendation 2.3 (Moderate Sell)

CLOV Stock Price Chart Interactive Chart >

Price chart for CLOV

CLOV Price/Volume Stats

Current price $2.13 52-week high $14.17
Prev. close $2.25 52-week low $1.95
Day low $2.09 Volume 8,315,828
Day high $2.26 Avg. volume 12,489,012
50-day MA $2.54 Dividend yield N/A
200-day MA $4.19 Market Cap 1.01B

Clover Health Investments Corp. Cl A (CLOV) Company Bio

Clover Health Investments, Corp. provides health insurance services. The company was founded in 2012 and is based in Franklin, Tennessee.

CLOV Latest News Stream

Event/Time News Detail
Loading, please wait...

CLOV Latest Social Stream

Loading social stream, please wait...

View Full CLOV Social Stream

Latest CLOV News From Around the Web

Below are the latest news stories about Clover Health Investments Corp that investors may wish to consider to help them evaluate CLOV as an investment opportunity.

Clover Health Investments, Corp. (CLOV) CEO Vivek Garipalli on Q4 2021 Results - Earnings Call Transcript

Clover Health Investments, Corp. (CLOV) Q4 2021 Earnings Conference Call February 23, 2022, 05:00 PM ET Company Participants Derrick Nueman - VP of IR Vivek Garipalli - CEO Andrew Toy - President and CTO Mark Herbers - CFO Conference Call Participants Richard Close - Canaccord Genuity Jonathan Yong - Credit...

SA Transcripts on Seeking Alpha | February 24, 2022

Clover Health Gains 14.9% on Higher Q4 Revenues

Clover Health (CLOV) has delivered a stellar performance in the fourth quarter of 2021, as both earnings and revenues exceeded expectations. Shares of the next-generation healthcare company have rallied 14.9% in Wednesday’s extended trading session to close at $2.31. Total revenues of $432 million surpassed analysts’ expectations of $408.1 million. The company had reported total revenues of $166.2 million in the fourth quarter of 2020. Markedly, revenues consist of $201 million in premiums earned and $228.6 million of Direct Contracting revenue. As of December 31, 2021, while lives under Clover Management were about 129,996, up 124% year-over-year, lives under Clover Assistant Management grew 223% to about 96,000.

Radhika Saraogi on TipRanks | February 24, 2022

7 Popular Stocks That Pros Agree You Should Punt From Your Portfolio

These stocks to sell run the gamut in terms of industry, but they all have one thing in common: the pros think they ought to be sold.

Alex Sirois on InvestorPlace | February 23, 2022

Is CLOV Stock a Buy at 52-Week Lows? 3 Analysts Weigh In on Clover Health.

Here's what some expert analysts think about Clover Health and CLOV stock amid the stock's impressive decline to new 52-week lows.

Chris MacDonald on InvestorPlace | February 23, 2022

Clover Health Reports Fourth Quarter 2021 Financial Results

Fourth quarter total revenue was $432.0 million, up 160% year-over-year, enabled by a wide, open network designed to serve all Medicare lives Lives under Clover Assistant Management increased 223% year-over-year 2022 total revenue expected to exceed $3 billion driven by projected 90% year-over-year growth in lives under management Clover expects 2022 operating expenses as a percentage of revenue and the Medical Care Ratio (MCR) for its Medicare Advantage (MA) plans to decrease meaningfully from

Yahoo | February 23, 2022

Read More 'CLOV' Stories Here

CLOV Price Returns

1-mo N/A
3-mo -40.00%
6-mo -42.74%
1-year -84.06%
3-year N/A
5-year N/A
YTD -42.74%
2021 -77.82%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5522 seconds.